Why Is Insulin Glargine-Yfgn So Hard to Find? [Explained for 2026]

If you've been trying to fill a prescription for insulin glargine-yfgn — sold under the brand name Semglee — and keep hitting dead ends at the pharmacy, you're not alone. Millions of patients who rely on this long-acting basal insulin have faced serious access challenges since 2025, and the situation became even more complicated in early 2026. This article explains exactly what happened, why insulin glargine-yfgn is so difficult to find, and what your options are right now.

What Is Insulin Glargine-Yfgn (Semglee)?

Insulin glargine-yfgn is a long-acting biosimilar insulin approved by the FDA on July 28, 2021 — making it the first interchangeable biosimilar insulin product ever approved in the United States. It is biosimilar to and interchangeable with Lantus (insulin glargine), the widely prescribed basal insulin made by Sanofi.

Because it carried the FDA's "interchangeable" designation, pharmacists could substitute insulin glargine-yfgn for Lantus at the point of dispensing — without needing a new prescription from your doctor. This made it a popular, lower-cost alternative for patients and insurers alike. It was available as Semglee (the branded version) and as unbranded insulin glargine-yfgn.

The Short Answer: Semglee Was Discontinued in December 2025

The biggest reason insulin glargine-yfgn is hard to find in 2026 is the market exit of Semglee. Biocon Biologics, the manufacturer of Semglee, formally discontinued both the Semglee vials and pens on December 31, 2025. This was not an FDA action or a safety recall — it was a business decision by the manufacturer.

The discontinuation created an immediate wave of disruption. Millions of patients who had been stabilized on Semglee — or whose insurance plans covered Semglee as their preferred basal insulin — suddenly needed to find an alternative. Insurance formularies scrambled to update coverage, and pharmacies saw a surge in demand for Lantus, Basaglar, and other glargine products.

Timeline: How the Insulin Glargine-Yfgn Shortage Developed

The access challenges didn't happen overnight. Here's how the situation unfolded:

Early 2025: Biocon announced an anticipated shortage of branded and unbranded Semglee pens. The company expected to resolve it quickly, but the shortage persisted.

March 2025: Multiple insurers — including Blue Cross NC — added Lantus to formularies as an emergency alternative. Since Semglee is interchangeable with Lantus, members could switch without a new prescription.

August 2025: Regional shortages of Semglee and insulin glargine-yfgn intensified, particularly in the Pacific Northwest and Northeast.

December 31, 2025: Biocon formally discontinued all Semglee vials and pens.

January 1, 2026: Civica Rx, a nonprofit pharmaceutical company, launched its own unbranded insulin glargine-yfgn prefilled pens at $45 for a box of five pens — the lowest list price for any long-acting insulin on the market. In California, the product is sold under the CalRx brand.

Is Insulin Glargine-Yfgn Completely Gone?

No — and this is an important distinction. While the Semglee brand is discontinued, unbranded insulin glargine-yfgn is still being manufactured and distributed in 2026. Civica Rx launched its version in January 2026, and generic insulin glargine-yfgn vials and pens from other manufacturers (including Winthrop) also remain available. However, not every pharmacy stocks every version, and availability varies significantly by region and pharmacy.

According to ASHP drug shortage data updated July 2026, the generic vials and pens of insulin glargine-yfgn are available, but supply varies. Pharmacy-level availability is inconsistent, particularly in areas that were previously well-supplied with Semglee.

38,224+ patients found their medications in stock

38K+

Find Insulin Glargine-Yfgn In Stock Today →

Why Do Some Pharmacies Still Not Have It?

Even with generic versions available, several factors make it hard to find at your specific pharmacy:

Formulary chaos: Many insurance plans had Semglee as their preferred or sole covered insulin glargine product. Updating formularies to cover alternative products — and getting those updates to actually work at the pharmacy counter — takes time.

Demand surge: When millions of Semglee patients shifted to Lantus and other products simultaneously, pharmacies saw demand spikes they weren't prepared for.

Ordering gaps: Independent pharmacies and smaller chains may not have established supplier relationships with the new manufacturers of unbranded insulin glargine-yfgn.

Product confusion: Patients, pharmacists, and insurers are all navigating unfamiliar product names, NDC numbers, and coverage rules simultaneously.

What Are Your Options Right Now?

If you're struggling to find insulin glargine-yfgn, here are the most important steps to take:

Ask specifically for unbranded insulin glargine-yfgn: The Civica Rx version launched in January 2026 and is available through pharmacies that carry it at $45 for a 5-pen box.

Call multiple pharmacies: Availability varies dramatically by location. Large chains like CVS, Walgreens, and Costco may have different stock than your local independent pharmacy.

Ask about interchangeable substitutes: Since insulin glargine-yfgn is interchangeable with Lantus, your pharmacist can substitute Lantus without a new prescription if insulin glargine-yfgn is not available.

Talk to your doctor: Other basal insulins — including Basaglar, Rezvoglar, Toujeo, and Levemir — may be appropriate alternatives. Some may require a new prescription.

Use medfinder:[@portabletext/react] Unknown block type "span", specify a component for it in the `components.types` prop calls pharmacies near you to check which ones can fill your insulin glargine-yfgn prescription, so you don't have to spend hours on the phone.

Skip the calls, skip the stress.

Find Insulin Glargine-Yfgn In Stock Today →

50K+

Medications
Found

99%

Success
Rate

6+

Hours saved
on average

The Bottom Line

Insulin glargine-yfgn is hard to find in 2026 primarily because the Semglee brand was discontinued on December 31, 2025, triggering a market-wide realignment of insulin glargine supply and insurance coverage. The drug itself still exists as an unbranded generic, but navigating the new supply landscape takes effort.

For step-by-step guidance on actually locating insulin glargine-yfgn at a pharmacy near you, read our guide: How to Find Insulin Glargine-Yfgn in Stock Near You.